Complementary Medications and outcomes in CCTG trials.

Palliative and supportive care presentation at ESMO 2019

Approximately a fifth of patients participating in phase III breast, lung, or colorectal cancer clinical trials conducted by CCTG also used complementary medicines.

More >>
 
CCTG IND234 prostate precision medicine trial - Dr. Kim Chi

Innovative study advances personalized medicine for prostate cancer patients

CCTG IND224 is a new clinical trial, opening across Canada, is considered a major advancement in precision medicine for prostate cancer and the first of its kind in the world.

More >>
 
CCTG LY16 | RELEVANCE published in New England Journal of Medicine

CCTG LY16 | RELEVANCE published in New England Journal of Medicine

The results of the CCTG LY16 trial of Rituxmab plus Lenalidomide in Advanced Untreated Follicular Lymphoma (RELEVANCE), recently published in New England Journal of Medicine, has the potential to offer a new treatment option to lymphoma patients, that does not require chemotherapy.

More >>
 
Precision medicine targeting each individuals unique form of cancer

The rise of precision medicine

Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.  

More >>
 

Planned trials

ALC5

Novel Therapeutics vs Azacitidine in Patients with AML or High Risk Myelodysplastic Syndrome, Aged 60 or Older (LEAP, Intergroup Less Intense AML Platform Trial)

More >>

CRC9

Circulating Tumor DNA as a Predictive Marker for Response to Chemotherapy in Pts with Stage II Colon Ca

HDC1

Nivolumab or Brentuximab Vedotin plus AVD in Pts (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

More >>

I239

CFI-400945 and Durvalumab in Patients with Advanced/Metastatic Triple Negative Breast Cancer

More >>

LY18

A Phase I Master Protocol of Novel Combination Therapy for Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma

More >>

MAC25

Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2 Positive Metastatic Breast Cancer

More >>

OV26

Maintenance Therapy with Olaparib and Cediranib or Olaparib Alone in Relapsed Platinum-sensitive Ovarian Cancer Following a Response to Platinum-Based Chemotherapy

More >>

PR22

Darolutamide Augments Standard Therapy for Localized High-Risk Prostate Cancer (DASL-HiCaP)

More >>

Recently activated

BR36

Study of Molecular Response Adaptive Immuno-Chemotherpay in Patients with NSCLC

More >>

BRC7

INSIGNA: Firstline Immunotherapy alone or in Combination with Chemo in Induction/Maintenance or Post Progression in Adv NSCLC with Immunobiomarker SIGNature-driven Analysis

More >>

ENC1

Carboplatin & Paclitaxel with or without Pembrolizumab for Measurable Stage 3 or 4A, Stage 4B or Recurrent Endometrial Cancer

More >>

HNC2

Radiotherapy with Concurrent MEDI4736 vs Radiotherapy with Concurrent Cetuximab in Pts with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin

More >>

I238

Durvalumab Ttreatment in Patients who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity

More >>

MAC26

Testing the Addition of the Study Drug Olaparib to the Usual Radiotherapy in Inflammatory Breast Cancer Patients

More >>
Precision medicine targeting each individuals unique form of cancer

The rise of precision medicine

Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.  

More >>
 
TAILORx / MAC.12 breast cancer trial showed no benefit from chemotherapy for 70% of women with the most common form of breast cancer.

TAILORx | MAC12 trial showed no benefit from chemotherapy for women with breast cancer

Clinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment.

More >>
 

Study results suggest that a new pancreatic cancer treatment regimen should become standard practice world-wide

Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.

More >>
 
Award recipients

Canadian Cancer Research Alliance announces award winners

Canadian Cancer Research Alliance has announced the recipients of their 2017 awards: former CCTG Director, Dr. Elizabeth Eisenhauer will recieve the Exceptional Leadership in Cancer Research award and Ms. Judy Needham will receive the Exceptional Leadership in Patient Involvement in Cancer award.

More >>
 

Publications

CO.28: Neoadjuvant Chemotherapy, Excision and Observation (NEO) for early rectal cancer

J Clin Oncol 37: TPS724 - TPS724, 2019
Kennecke HF;Brown CJ;Auer R;Drolet S;Eng C;Gordon VL;Hochman DJ;Moloo H;Wei AC;Chan K;Montenegro A;Loree JM;Tu D;Jonker DJ;

More >>

A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study (ONLINE)

Invest New Drugs , 2019
Lapointe S;Mason W;MacNeil M;Harlos C;Tsang R;Sederias J;Luchman HA;Weiss S;Rossiter JP;Tu D;Seymour L;Smoragiewicz M;

More >>

Randomized phase II trial and tumor mutational spectrum analysis from cabozantinib versus chemotherapy in metastatic uveal melanoma (Alliance A091201) (ONLINE)

Clin Cancer Res : clincanres, 2019
Luke JJ;Olson DJ;Allred JB;Strand CA;Bao R;Zha Y;Carll T;Labadie BW;Bastos BR;Butler MO;Hogg D;Munster PN;Schwartz GK;

More >>

Optimizing whole brain radiotherapy dose and fractionation: Results from a prospective phase III trial (NCCTG N107C (Alliance)/CEC.3) (ONLINE)

International Journal of Radiation Oncology*Biology*Physics , 2019
Trifiletti DM;Ballman KV;Brown PD;Anderson SK;Carrero XW;Cerhan JH;Whitton AC;Greenspoon J;Parney IF;Laack NN;Ashman JB;Bahary JP;Hadjipanayis CG;Urbanic JJ;Barker FG;Farace E;Khuntia D;Giannini C;Buckner JC;Galanis E;Roberge D;

More >>

Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial

J Clin Oncol 37: 2338 - 2348, 2019
Muss HB;Polley MY;Berry DA;Liu H;Cirrincione CT;Theodoulou M;Mauer AM;Kornblith AB;Partridge AH;Dressler LG;Cohen HJ;Kartcheske PA;Perez EA;Wolff AC;Gralow JR;Burstein HJ;Mahmood AA;Sutton LM;Magrinat G;Parker BA;Hart RD;Grenier D;Hurria A;Jatoi A;Norton L;Hudis CA;Winer EP;Carey L;

More >>

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer

N Engl J Med 380: 2395 - 2405, 2019
Sparano JA;Gray RJ;Ravdin PM;Makower DF;Pritchard KI;Albain KS;Hayes DF;Geyer CE;Dees EC;Goetz MP;Olson JA;Lively T;Badve SS;Saphner TJ;Wagner LI;Whelan TJ;Ellis MJ;Paik S;Wood WC;Keane MM;Gomez Moreno HL;Reddy PS;Goggins TF;Mayer IA;Brufsky AM;Toppmeyer DL;Kaklamani VG;Berenberg JL;Abrams J;Sledge GW;

More >>

Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer

Pharmacogenetics and Genomics 29: 183 - 191, 2019
Ingle JN;Kalari KR;Momozawa Y;Kubo M;Furukawa Y;Shepherd LE;Ellis MJ;Goss PE;Barman P;Carlson EE;Sinnwell JP;Tang X;Goetz MP;Chen BE;Cairns J;Weinshilboum RM;Wang L;

More >>

Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial (ONLINE)

JAMA Oncology , 2019
Sparano JA;Gray RJ;Makower DF;Albain KS;Saphner TJ;Badve SS;Wagner LI;Kaklamani VG;Keane MM;Gomez HL;Reddy PS;Goggins TF;Mayer IA;Toppmeyer DL;Brufsky AM;Goetz MP;Berenberg JL;Mahalcioiu C;Desbiens C;Hayes DF;Dees EC;Geyer CE Jr;Olson JA;Wood WC;Lively T;Paik S;Ellis MJ;Abrams J;Sledge GW;

More >>